<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Murray-Stewart T</submitter><funding>Maryland Cigarette Restitution Fund</funding><funding>Samuel Waxman Cancer Research Foundation</funding><funding>NCI NIH HHS</funding><funding>National Institutes of Health</funding><funding>National Institute of Biomedical Imaging and Bioengineering</funding><pagination>e0175917</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5396973</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(4)</volume><pubmed_abstract>Synthesizing polycationic polymers directly from existing drugs overcomes the drug-loading limitations often associated with pharmacologically inert nanocarriers. We recently described nanocarriers formed from a first-generation polyamine analogue, bis(ethyl)norspermine (BENSpm), that could simultaneously target polyamine metabolism while delivering therapeutic nucleic acids. In the current study, we describe the synthesis and evaluation of self-immolative nanocarriers derived from the second-generation polyamine analogue PG-11047. Polyamines are absolutely essential for proliferation and their metabolism is frequently dysregulated in cancer. Through its effects on polyamine metabolism, PG-11047 effectively inhibits tumor growth in cancer cell lines of multiple origins as well as in human </pubmed_abstract><journal>PloS one</journal><pubmed_title>Biochemical evaluation of the anticancer potential of the polyamine-based nanocarrier Nano11047.</pubmed_title><pmcid>PMC5396973</pmcid><funding_grant_id>EB015216</funding_grant_id><funding_grant_id>S30-CA006973</funding_grant_id><funding_grant_id>R01-CA204345</funding_grant_id><funding_grant_id>EB014570</funding_grant_id><funding_grant_id>R01 CA204345</funding_grant_id><pubmed_authors>Oupicky D</pubmed_authors><pubmed_authors>Xie Y</pubmed_authors><pubmed_authors>Ferrari E</pubmed_authors><pubmed_authors>Marton LJ</pubmed_authors><pubmed_authors>Murray-Stewart T</pubmed_authors><pubmed_authors>Yu F</pubmed_authors><pubmed_authors>Casero RA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Biochemical evaluation of the anticancer potential of the polyamine-based nanocarrier Nano11047.</name><description>Synthesizing polycationic polymers directly from existing drugs overcomes the drug-loading limitations often associated with pharmacologically inert nanocarriers. We recently described nanocarriers formed from a first-generation polyamine analogue, bis(ethyl)norspermine (BENSpm), that could simultaneously target polyamine metabolism while delivering therapeutic nucleic acids. In the current study, we describe the synthesis and evaluation of self-immolative nanocarriers derived from the second-generation polyamine analogue PG-11047. Polyamines are absolutely essential for proliferation and their metabolism is frequently dysregulated in cancer. Through its effects on polyamine metabolism, PG-11047 effectively inhibits tumor growth in cancer cell lines of multiple origins as well as in human </description><dates><release>2017-01-01T00:00:00Z</release><publication>2017</publication><modification>2026-05-05T19:37:44.244Z</modification><creation>2019-03-27T02:41:36Z</creation></dates><accession>S-EPMC5396973</accession><cross_references><pubmed>28423064</pubmed><doi>10.1371/journal.pone.0175917</doi></cross_references></HashMap>